Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

15.0%

6 terminated/withdrawn out of 40 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

48%

19 trials in Phase 3/4

Results Transparency

0%

0 of 24 completed trials have results

Key Signals

3 recruiting6 terminated

Enrollment Performance

Analytics

Phase 3
19(48.7%)
Phase 2
18(46.2%)
Phase 1
1(2.6%)
Early Phase 1
1(2.6%)
39Total
Phase 3(19)
Phase 2(18)
Phase 1(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (40)

Showing 20 of 40 trials
NCT05441488Phase 3Suspended

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Role: lead

NCT06280755Recruiting

Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.

Role: collaborator

NCT05564169Phase 3Not Yet Recruiting

Masitinib in Patients With Mild Alzheimer's Disease

Role: lead

NCT07174492Phase 3Not Yet Recruiting

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

Role: lead

NCT05211570Phase 1Recruiting

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT03127267Phase 3Recruiting

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Role: lead

NCT01872598Phase 3Completed

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Role: lead

NCT02588677Phase 2Completed

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT03761225Phase 3Completed

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Role: lead

NCT04333108Phase 3Unknown

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Role: lead

NCT04622865Phase 2Unknown

Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Role: lead

NCT05047783Phase 2Unknown

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Role: lead

NCT05449444Phase 2Unknown

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Role: lead

NCT00812240Phase 3Terminated

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Role: lead

NCT05200169Early Phase 1Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects

Role: lead

NCT01449162Phase 3Completed

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Role: lead

NCT03556956Phase 2Completed

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Role: lead

NCT03766295Phase 3Completed

Masitinib Plus Gemcitabine in Pancreatic Cancer

Role: lead

NCT02490488Phase 2Completed

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

Role: lead

NCT01694277Phase 3Completed

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Role: lead